Avstera Therapeutics
Malvern, US · Founded 2021 · Delaware corporation
Founders & leadership
KM
Karthik MusunuriNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$8.6M disclosed across 3 rounds · 2021–2023
▶$5MraisedOct 2023 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedOct 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ajay RajuDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3.5MraisedMay 2022 · 3 investors · BiotechnologyRule 506(b)
▶$3.5MraisedMay 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ajay RajuDirector
- Karthik MusunuriExecutive Officer
- Offering amount
- $6M
- Amount sold
- $3.5M
- Proceeds to insiders
- $300K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$100KraisedAug 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedAug 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Karthik MusunuriExecutive Officer
- Amount sold
- $100K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Avstera Therapeutics raised?
- Avstera Therapeutics has disclosed $8.6M raised across 3 rounds.
- Where is Avstera Therapeutics headquartered?
- Avstera Therapeutics is headquartered in Malvern, US.